secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013663
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026
------------------------------------------------------------------------

- Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.
- Topline results expected Q3 2026, followed by BLA submission and planned commercial launch for NXC-201.
- Onboarded Chief Medical Officer Richard Graydon, MD, PhD, formerly of Merck and Johnson & Johnson.
- NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations; market for AL Amyloidosis estimated at $6B in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/0001493152-26-013663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer